These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17000683)

  • 21. Phase I study of docetaxel and topotecan in patients with advanced malignancies.
    Dubey S; Hutson P; Alberti D; Arzoomanian R; Binger K; Volkman J; Feierabend C; Wilding G; Schiller JH
    J Oncol Pharm Pract; 2005 Dec; 11(4):131-8. PubMed ID: 16595064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
    Panetta JC; Schaiquevich P; Santana VM; Stewart CF
    Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
    Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
    Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients.
    Ozawa K; Minami H; Sato H
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):551-7. PubMed ID: 18064462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
    Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
    J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose schedule optimization and the pharmacokinetic driver of neutropenia.
    Patel M; Palani S; Chakravarty A; Yang J; Shyu WC; Mettetal JT
    PLoS One; 2014; 9(10):e109892. PubMed ID: 25360756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
    Fernández-Teruel C; Lubomirov R; Fudio S
    J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
    Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
    Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug interactions with the taxanes: clinical implications.
    Baker AF; Dorr RT
    Cancer Treat Rev; 2001 Aug; 27(4):221-33. PubMed ID: 11545542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
    Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
    Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
    Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.
    Léger F; Loos WJ; Fourcade J; Bugat R; Goffinet M; Mathijssen RH; Verweij J; Sparreboom A; Chatelut E
    Br J Cancer; 2004 Jan; 90(2):343-7. PubMed ID: 14735174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
    Markman J; Zanotti K; Webster K; Belinson J; Peterson G; Kulp B; Markman M
    Gynecol Oncol; 2004 Feb; 92(2):592-5. PubMed ID: 14766252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.